bioMérieux S.A. services

bioMérieux aims to advance the impact of Clinical Diagnostic in Healthcare by effectively developing and delivering to the market innovative solutions that address significant unmet operational and medical needs, contributing to fight the rise of antimicrobial resistance and to better manage acute conditions linked to infections.

A Renal “Alarm System”: Acute kidney injury is increasingly prevalent,1 but unlike myocardial infarction, AKI often has no signs or symptoms, making risk assessment via traditional methods difficult.2 The NephroCheck Test, designed to help you evaluate critically ill patients’ risk of acute kidney injury, is a breakthrough in renal risk assessment.

A Key Advancement for Addressing a Dangerous Condition. The NephroCheck® Test was developed in response to the mounting personal and financial costs of acute kidney injury,1 along with the difficulty of assessing risk in the absence of signs and symptoms, as opposed to such conditions as myocardial infarction.2 The test is designed to meet the rising need for risk assessment.